News Releases


2015 | 2014 | 2013 | Archive
Keyword Search
 
DateTitle 
06/17/15ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
SAN DIEGO--(BUSINESS WIRE)--Jun. 17, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation w... 
Printer Friendly Version
06/16/15ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
Data from Integrated Analysis of Two Phase III Studies Show Robust and Consistent Efficacy of NUPLAZID Across a Wide Array of Study Measures Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Jun. 16, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company ... 
Printer Friendly Version
05/26/15ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
SAN DIEGO--(BUSINESS WIRE)--May 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2015 Healthcare Conference on Tuesday, June 2, 2015, at 1:30 p.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation will be a... 
Printer Friendly Version
05/07/15ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2015. ACADIA reported a net loss of $40.4 million, or $0.40 per common share, ... 
Printer Friendly Version
05/06/15ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
SAN DIEGO--(BUSINESS WIRE)--May 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015, at 4:20 p.m. Pacific Time in Las Vegas. A live webcast of ACADIA’s pres... 
Printer Friendly Version
04/30/15ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results ... 
Printer Friendly Version
04/07/15ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
SAN DIEGO--(BUSINESS WIRE)--Apr. 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation wi... 
Printer Friendly Version
03/26/15ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Mar. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceuti... 
Printer Friendly Version
03/11/15ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
Steve Davis Appointed Interim Chief Executive Officer SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Boa... 
Printer Friendly Version
03/11/15ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
Conference Call Scheduled for Today, March 11, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today provided an update on the planned timing of its NUPLAZIDTM (pimavanserin) New Drug A... 
Printer Friendly Version
02/26/15ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
SAN DIEGO--(BUSINESS WIRE)--Feb. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2014. ACADIA reported a net loss of $28.4 million, or $0.28 per common share,... 
Printer Friendly Version
02/24/15ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Feb. 24, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015, at 10:40 a.m. Eastern Time in Bost... 
Printer Friendly Version
02/19/15ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
ACADIA to Host Conference Call and Webcast on Thursday, February 26, 2015, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 19, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial resu... 
Printer Friendly Version
01/06/15ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco. A live webcast of ACADIA’s presenta... 
Printer Friendly Version